No Result

View All Result

No products in the cart.

Home StudyGraphics

#VisualAbstract Clinical benefit seen with ibrutinib for relapsed/refractory multiple mantle cell lymphoma in a real-world population

byKathleen Lau

March 11, 2021

in StudyGraphics

#VisualAbstract: Circulating tumor DNA levels may predict treatment response in patients with advanced melanoma

RelatedReports

Mutation linked with decrease in cutaneous diffuse large B-cell lymphoma

Weekly Rewinds

2 Minute Medicine Rewind February 16, 2026

February 16, 2026

Pediatric palliative care outcome measures often miss quality of life

Pediatrics

Isotonic Fluids Reduce Hyponatremia in Hospitalized Children

February 4, 2026

Reduced venous recanalization after acute deep vein thrombosis associated with post-thrombotic syndrome

Chronic Disease

Effect of high elevation on deep vein thrombosis: a multicenter cohort study

January 22, 2026

Patients with advanced adenomas are at increased risk of developing colorectal cancer

AI Roundup

AstraZeneca moves to own multimodal oncology AI with Modella

January 21, 2026

RTS,SA/S01 anti-malarial vaccine efficacy wanes significantly over time

Screening plus Eave Tubes provides a cost-effective strategy to alleviate burden of malaria in Côte d’Ivoire

Epidemiologic features of the 2018-2019 measles outbreak in New York City

Study details societal costs of a measles outbreak

Thrombophilia-associated stillbirth risk appears limited to factor V Leiden

Resuming oral anticoagulant (OAC) therapy after an OAC-related bleed associated with higher rates of bleeding

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports